PAN INDIA DRUGS & CHEMICALS LIMITED
Yours Directors have pleasure in presenting their Third Annual Report
together with Audited Statement of Accounts for the year ended 31 st March
In order to conserve the resources and to strengthen the financial position
for future expansion, your Directors do not recommend any dividend.
The Company has completed implementation of the project at Indore and
production commenced with full vigour. The first consginment rolled out in
July 1994 and since then substantial progress made with achievement of
turnover of Rs. 466.82 lacs and a Net Profit of Rs.30.53 Lacs.
Your Company has registered exports during the year at Rs.26.32 lacs. The
Company has received substantial export orders during the current year for
existing and proposed products.
OUT LOOK FOR FUTURE
The Company is planning to implement the expasion project towards backward
integration for production of 3 4 5 Trimethoxybenyldihyde, the main raw
material for manufacture of TRIMETHOPRIM. which is being imported at
present. Apart from this, few vital Bulk Drugs having globle demand are
also planned for production. The Prospects of Bulk drugs & Pharmaceuticals
Industry in India are very bright.
The Company was sanctioned and disbursed a Term loan assistance of Rs.
60.00 lacs by the M.P Financial Corporation. State Bank of India, M.G.
Road, Indore has also sanctioned the working capital limits to the tune of
Rs.128.00 lacs. Including Export Packing Credit Limit and non fund based
limits. Your Directors are pleased to place on record their sincere
appreciation towards M.P. Financial Corporation and State Bank of India.
Mrs. Rajlaxmi Jain & Mr. D.P. Desai retire by rotation and being eligible
offer themselves for reappointment.
The Company has not accepted any deposits from public and have thus
complied with the provisions of section 58-A of the Companies Act, 1956 and
the Rules made thereunder and also the directives of the Reserve Bank of
PARTICULAR OF EMPLOYEES
During the year there were no employee drawing remuneration in excess of
the ceilings provided U/S 217 (2A) of the companies Act 1956 read with the
Companies (Particulars of employees Rules) 1975. No Employee holds more
than 2% of equity shares of the Company.
Notes contained in schedule 18 of the accounts referred to in the Auditors
report are self explanatory and do not call for further eXplanation and may
be treated as adequate in term of section 217 (3) of the Companies Act
M/s. Vijay K. Jain & Associates the present Auditors of the Company retire
on the conclusion of this Annual General Meeting and being eligible offer
themselves for reappointment.
Information regarding conservation of energy, absorptions of technology
etc. as required under section 217(3) of the Act is annexed as per Annexure
'A' forming part of this report.
Your Directors wish to place on record their sincere appreciation for the
continued co-operation, support and assistance provided during the year
under review by the Bankers, Financial institution and Government
authorities. Your Directors place on record their deep appreciation of the
dedicated services rendered by he employees at all levels. The Board would
also like to acknowledge the continued faith and confidence reposed by the
share-holders of the Company.
ANNEXURE TO THE DIRECTORS REPORT ANNEXURE 'A'
Information as per section 217 (1) (e) of the Companies Act, 1956 read with
the Companies (Disclose of Particulars in the Report of Board of Directors)
Rules, 1988 nd forming part of the Directors Report for the period ended
March 31, 1995.
CONSERVATION OF ENERGY
A. POWER & FUEL CONSUMPTION
Particulars 1994-95 1993-94
a) Purchases Units 55805 --
Total Amount Rs. 127305 --
b) own Generator
Through Diesel Generator Units 234 --
Steam Generator though Boiler 440000 --
2. L.D. Oil Consumed Ltrs. 21177.50 --
Total Amount Rs. 159397 --
3. Diesel Consumed Ltrs. 5200 --
Total Amount Rs. 40768 --
B. CONSUMPTION PER KG. OF PRODUCTION OF BULK DRUGS
Electricity units. 4.25
L.D.O. Ltrs. 1.60
Diesel Ltrs. 39
1. Research & Development
i) Specific Areas in which Research & Development Carried out by the
a) Drug Intermediates b) Cardio Vascular Drugs c) Anti Biotic Drugs
II) Benefits desired as a result of the above R&D Investment in Research &
Development are prerequisite of Pharmaceutical & bulk Drugs manufacturing
unit and its benefits are expected to reflect in the financial results of
iii) Future Plan & Action Company propose ot diversify into profitable and
less competitive areas specially on backward Integration of project.
iv) Expenditure on R&D (Rs in Lacs)
a) Capital 1.44 0.97
b) Recurring 0.98 --
2. Technology Absorption, Adaption & Innovation
1) Efforts in brief, made towards technology absorption, adaption &
Technology developed for Drug intermediates & anti cardiac vascular drugs &
anti biotic drugs are being absorbed & adapted.
2) Benefit derived as a result of above effects Improved Product range &
3) Technology improved during last 5 year - Nil.
FOREIGN EXCHANGE EARNING & OUTGO : (Rs.in Lacs.)
i) Foreign Exchange Earned 3.91 --
ii) C.I.F value of import
Raw material 61.67 --
Capital Goods --
iii) Foreign Tour 3.27 --
iv) Comission -- -
v) Subscription -- --
For and on behalf of the Board
Place : INDORE,
Dated : 10th November, 1995.